Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Shnaidman

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Biometrics|June 8, 2004
Bayesian analysis of serial dilution assaysAndrew Gelman, Ginger L Chew, Michael Shnaidman
Statistics in Medicine|February 3, 2016
Design and analysis of clinical trials in the presence of delayed treatment effectTony Sit, Mengling Liu, Michael Shnaidman, et al.
International Journal of Cancer|November 4, 2004
p53 autoantibodies predict subsequent development of cancerYongliang Li, Antti Karjalainen, Heikki Koskinen, et al.
British Journal of Haematology|July 6, 2017
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphomaNam H Dang, Michinori Ogura, Sylvie Castaigne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomasArun Rajan, Ronan J Kelly, Jane B Trepel, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Biometrics|June 8, 2004
Bayesian analysis of serial dilution assaysAndrew Gelman, Ginger L Chew, Michael Shnaidman
Statistics in Medicine|February 3, 2016
Design and analysis of clinical trials in the presence of delayed treatment effectTony Sit, Mengling Liu, Michael Shnaidman, et al.
International Journal of Cancer|November 4, 2004
p53 autoantibodies predict subsequent development of cancerYongliang Li, Antti Karjalainen, Heikki Koskinen, et al.
British Journal of Haematology|July 6, 2017
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphomaNam H Dang, Michinori Ogura, Sylvie Castaigne, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomasArun Rajan, Ronan J Kelly, Jane B Trepel, et al.
Pageof 1